Related Experiment Video
Updated: Feb 27, 2026
Intestinal Epithelial Regeneration in Response to Ionizing Irradiation
Published on: July 27, 2022
Simvastatin ameliorates ionizing radiation-induced apoptosis in the thymus by activating the AKT/sirtuin 1 pathway in
Hong Yang1, Fei Huang1, Yulong Tao1
1Department of Pharmacy, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China.
Abstract:
Simvastatin is a HMG-CoA reductase inhibitor widely used to lower plasma cholesterol and to protect against cardiovascular risk factors. The aim of this study was to investigate whether simvastatin attenuates ionizing radiation-induced damage in the mouse thymus and to elucidate the possible mechanisms invovled. For this purpose, male C57BL/6J mice aged 6 weeks were used and exposed to 4 Gy 60Co γ-radiation with or without simvastatin (20 mg/kg/day, for 14 days). Apoptosis was determined by terminal deoxynucleotidyltransferase-mediated dUTP nick-end labeling (TUNEL) assay or transmission electron microscopy (TEM) examination. Thymocytes were also isolated and incubated in DMEM supplemented with 10% FBS at 37˚C and exposed to 8 Gy 60Co γ-radiation with or without simvastatin (20 µM). The expression levels of Bcl-2, p53, p-p53, AKT, sirtuin 1 and poly(ADP-ribose) polymerase (PARP) were determined by western blot analysis. TUNEL and TEM examination revealed that simvastatin treatment significantly mitigated ionizing radiation-induced apoptosis in the mouse thymus. It was also found that simvastatin treatment increased AKT/sirtuin 1 expression following exposure to ionizing radiation in vivo and in vitro. In the in vivo model, but not in the in vitro model, Bcl-2 and PARP expression was augmented and that of p53/p-p53 decreased following treatment with simvastatin. On the whole, our findings indicate that simvastatin exerts a protective effect against ionizing radiation-induced damage in the mouse thymus, which may be partially attributed to the activation of the AKT/sirtuin 1 pathway.
Insights
Simvastatin protects the mouse thymus from radiation damage by reducing apoptosis. This effect is linked to the activation of the AKT/sirtuin 1 pathway, offering a potential therapeutic strategy against radiation-induced injury.
Area of Science:
- Radiation Biology
- Pharmacology
- Immunology
Background:
- Simvastatin, a HMG-CoA reductase inhibitor, is used to manage cholesterol and cardiovascular risks.
- Ionizing radiation causes significant damage, particularly to radiosensitive tissues like the thymus.
- Understanding protective mechanisms against radiation damage is crucial for therapeutic interventions.
Purpose of the Study:
- To investigate simvastatin's protective effects against ionizing radiation-induced damage in the mouse thymus.
- To elucidate the molecular mechanisms underlying simvastatin's radioprotective action.
Main Methods:
- Mice were exposed to 4 Gy gamma radiation with or without simvastatin treatment (20 mg/kg/day for 14 days).
- Apoptosis was assessed using TUNEL assay and transmission electron microscopy (TEM).
- In vitro studies involved exposing isolated thymocytes to 8 Gy radiation with simvastatin (20 µM), followed by Western blot analysis for key proteins (Bcl-2, p53, AKT, sirtuin 1, PARP).
Main Results:
- Simvastatin significantly mitigated radiation-induced apoptosis in the mouse thymus, confirmed by TUNEL and TEM.
- Simvastatin treatment increased AKT and sirtuin 1 expression both in vivo and in vitro following radiation exposure.
- In vivo, simvastatin also upregulated Bcl-2 and PARP expression while downregulating p53/p-p53 levels.
Conclusions:
- Simvastatin demonstrates a protective effect against ionizing radiation-induced damage in the mouse thymus.
- The radioprotective mechanism may involve the activation of the AKT/sirtuin 1 pathway.
- Simvastatin's potential as a radioprotective agent warrants further investigation.
